Oxaliplatine Teva

Oxaliplatin, the active ingredient in Oxaliplatine Teva, is a platinum‑based chemotherapy presented as a strength/form for intravenous use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic agent used in the treatment of cancers that involve the gastrointestinal tract and related pathways.

- Colorectal cancer: improves survival when combined with fluorouracil and leucovorin. - Gastric cancer: used as part of combination regimens for advanced disease. - Pancreatic cancer: contributes to tumour response in multi‑drug protocols. - Ovarian cancer: employed in certain platinum‑sensitive relapse settings. - Esophageal cancer: added to standard chemotherapy backbones for better disease control.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Diarrhoea: loose stools that may require supportive care. - Fatigue: generalized tiredness during treatment cycles. - Myelosuppression: reduced blood cell counts, increasing infection risk.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or hypersensitivity requiring immediate medical attention. - Acute pulmonary toxicity: breathing difficulties and reduced oxygen exchange. - Severe neutropenia: markedly low neutrophil counts leading to infection. - Thrombocytopenia: low platelet counts causing bleeding tendencies. - Cardiotoxicity: rare heart rhythm disturbances or myocardial injury.

When using Oxaliplatin, clinicians should assess patient suitability and monitor for adverse events throughout therapy.

- Renal function: evaluate baseline creatinine and adjust if impairment is present. - Neuropathy risk: monitor for sensory changes and modify dosing if symptoms progress. - Hematologic monitoring: perform regular CBCs to detect myelosuppression. - Hypersensitivity: be prepared to manage infusion‑related reactions. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, requiring careful review.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use with high‑dose cisplatin or aminoglycosides may worsen renal injury. - Anticoagulants: increased bleeding risk when combined with warfarin or direct oral anticoagulants.

Moderate Interactions (Monitor Closely): - Antiemetics: certain serotonin‑receptor antagonists can alter oxaliplatin clearance. - CYP450 inducers: drugs like rifampicin may reduce plasma exposure. - Radiotherapy: combined modality may heighten neurotoxicity. - Herbal supplements: St St  ??